Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ZES
MCID: ZLL002
MIFTS: 59

Zollinger-Ellison Syndrome (ZES)

Categories: Endocrine diseases, Gastrointestinal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Zollinger-Ellison Syndrome

About this section

MalaCards integrated aliases for Zollinger-Ellison Syndrome:

Name: Zollinger-Ellison Syndrome 12 53 59 37 29 55 44 15 73
Gastrinoma 53 59 73
Pancreatic Ulcerogenic Tumor Syndrome 53
Zollingerellison Syndrome 76
Z E Syndrome 53
Zes 53

Characteristics:

Orphanet epidemiological data:

59
zollinger-ellison syndrome
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (Worldwide); Age of onset: Adult; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare gastroenterological diseases
Rare endocrine diseases


Sources

Summaries for Zollinger-Ellison Syndrome

About this section
NIH Rare Diseases : 53 Zollinger-Ellison syndrome (ZES) is a condition in which tumors called gastrinomas in the pancreas and duodenum (part of the small intestine) cause high levels of the hormone gastrin in the blood. High levels of gastrin then cause production of too much stomach acid. Signs and symptoms may include abdominal pain, peptic ulcers, vomiting blood, and diarrhea. The tumors are sometimes cancerous and may spread to other areas of the body. In most cases, the cause of ZES is unknown. However, about 25-30% of gastrinomas are caused by an inherited condition called multiple endocrine neoplasia type 1 (MEN1). Treatment for ZES may include medication to reduce the production of stomach acid, and surgery for peptic ulcers or to remove tumors.

MalaCards based summary : Zollinger-Ellison Syndrome, also known as gastrinoma, is related to multiple endocrine neoplasia, type i and multiple endocrine neoplasia, and has symptoms including dyspepsia An important gene associated with Zollinger-Ellison Syndrome is SCT (Secretin), and among its related pathways/superpathways are Gastric acid secretion and Signaling by GPCR. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include pancreas, testes and pituitary, and related phenotypes are weight loss and jaundice

Disease Ontology : 12 A syndrome that is haracterized by the development of a one or more tumors (gastrinoma) in the pancreas, duodenum, or both that secrete excessive levels of gastrin, a hormone that stimulates production of acid by the stomach.

Wikipedia : 76 Zollinger�??Ellison syndrome (ZES) is a disease in which tumors cause the stomach to produce too much... more...

Sources

Related Diseases for Zollinger-Ellison Syndrome

About this section

Diseases related to Zollinger-Ellison Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 148)
# Related Disease Score Top Affiliating Genes
1 multiple endocrine neoplasia, type i 32.0 CHGA GAST GHRH MEN1 SCT SST
2 multiple endocrine neoplasia 31.5 CHGA MEN1
3 gastrinoma 31.0 CHGA GAST MEN1 SCT SST
4 hyperparathyroidism 31.0 CHGA GAST MEN1
5 gastritis 30.8 CHGA GAST HRH2
6 peptic ulcer disease 30.8 GAST HRH2 MEN1 SCT
7 steatorrhea 30.8 SCT SST
8 duodenal ulcer 30.7 GAST HRH2 SCT SST
9 pernicious anemia 30.6 GAST SST
10 primary hyperparathyroidism 30.6 CHGA GAST MEN1
11 pancreatic gastrinoma 30.5 MEN1 SCT
12 islet cell tumor 30.5 CHGA GAST MEN1 SST
13 peptic ulcer perforation 30.4 GAST HRH2
14 acromegaly 30.3 GHRH MEN1 SST
15 insulinoma 30.3 CHGA MEN1 SCT SST
16 hyperinsulinemic hypoglycemia 30.2 MEN1 SST
17 duodenal disease 30.2 MEN1 SCT SST
18 mixed ductal-endocrine carcinoma 30.1 CHGA GAST SST
19 atrophic gastritis 30.1 CHGA GAST SST
20 parathyroid adenoma 30.1 CHGA MEN1
21 small cell cancer of the lung 30.1 CHGA GAST SST
22 duodenal gastrinoma 30.0 CHGA GAST MEN1 SCT SST
23 gastroesophageal reflux 30.0 GAST HRH2 NTS
24 autoimmune atrophic gastritis 30.0 CHGA GAST
25 pheochromocytoma 30.0 CHGA MEN1 SST
26 carcinoid syndrome 30.0 CHGA GHRH MEN1 NTS SST
27 esophageal disease 29.9 GAST HRH2
28 ectopic cushing syndrome 29.9 MEN1 SST
29 somatostatinoma 29.9 CHGA SST
30 glucagonoma 29.8 CHGA GHRH SCT SST
31 gastric neuroendocrine neoplasm 29.7 CHGA GAST SST
32 neuroendocrine tumor 29.5 CHGA GAST MEN1 NTS SST
33 gastric gastrinoma 12.2
34 pancreatic neuroendocrine tumor 11.1
35 bronchopulmonary dysplasia 11.1
36 primary ciliary dyskinesia 11.1
37 diarrhea 10.6
38 esophagitis 10.5
39 cystadenocarcinoma 10.5
40 conn's syndrome 10.5
41 peptic esophagitis 10.5
42 cystadenoma 10.5
43 helicobacter pylori infection 10.4
44 adenocarcinoma 10.4
45 mucinous cystadenocarcinoma 10.4
46 crohn's disease 10.3
47 ovarian mucinous cystadenocarcinoma 10.3
48 ovarian cystadenocarcinoma 10.3
49 hypokalemia 10.3
50 pancreatitis 10.3

Graphical network of the top 20 diseases related to Zollinger-Ellison Syndrome:



Diseases related to Zollinger-Ellison Syndrome
Sources

Symptoms & Phenotypes for Zollinger-Ellison Syndrome

About this section

Human phenotypes related to Zollinger-Ellison Syndrome:

59 32 (show all 35)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
2 jaundice 59 32 occasional (7.5%) Occasional (29-5%) HP:0000952
3 multiple lipomas 59 32 occasional (7.5%) Occasional (29-5%) HP:0001012
4 intestinal obstruction 59 32 occasional (7.5%) Occasional (29-5%) HP:0005214
5 hyperparathyroidism 59 32 occasional (7.5%) Occasional (29-5%) HP:0000843
6 extrahepatic cholestasis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012334
7 glucagonoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0030404
8 increased glucagon level 59 32 occasional (7.5%) Occasional (29-5%) HP:0030688
9 adrenocortical carcinoma 59 32 very rare (1%) Very rare (<4-1%) HP:0006744
10 hypercalcemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003072
11 elevated circulating parathyroid hormone level 59 32 occasional (7.5%) Occasional (29-5%) HP:0003165
12 parathyroid hyperplasia 59 32 occasional (7.5%) Occasional (29-5%) HP:0008208
13 growth hormone excess 59 32 occasional (7.5%) Occasional (29-5%) HP:0000845
14 thyroid adenoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0000854
15 zollinger-ellison syndrome 59 32 obligate (100%) Obligate (100%) HP:0002044
16 episodic abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002574
17 peptic ulcer 59 32 hallmark (90%) Very frequent (99-80%) HP:0004398
18 pituitary prolactin cell adenoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0006767
19 adrenocortical adenoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0008256
20 pituitary growth hormone cell adenoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0011760
21 pituitary null cell adenoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0011761
22 esophagitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100633
23 pituitary corticotropic cell adenoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0008291
24 erythema 59 32 occasional (7.5%) Occasional (29-5%) HP:0010783
25 increased urinary cortisol level 59 32 occasional (7.5%) Occasional (29-5%) HP:0012030
26 hematochezia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002573
27 lipoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0012032
28 nausea 59 32 hallmark (90%) Very frequent (99-80%) HP:0002018
29 duodenal ulcer 59 32 hallmark (90%) Very frequent (99-80%) HP:0002588
30 neuroendocrine neoplasm 59 Obligate (100%)
31 gastrointestinal hemorrhage 59 Occasional (29-5%)
32 diarrhea 59 Very frequent (99-80%)
33 pituitary adenoma 59 Occasional (29-5%)
34 hypercortisolism 59 Occasional (29-5%)
35 increased circulating cortisol level 32 occasional (7.5%) HP:0003118

UMLS symptoms related to Zollinger-Ellison Syndrome:


dyspepsia

MGI Mouse Phenotypes related to Zollinger-Ellison Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.55 CHGA GAST GHRH HRH2 MEN1
2 homeostasis/metabolism MP:0005376 9.5 CHGA GAST GHRH HRH2 MEN1 NTS
3 nervous system MP:0003631 9.1 CHGA GHRH HRH2 MEN1 NTS SST
Sources

Drugs & Therapeutics for Zollinger-Ellison Syndrome

About this section

Drugs for Zollinger-Ellison Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4,Phase 1 103577-45-3, 138530-94-6 9578005
2
Lansoprazole Approved, Investigational Phase 4,Phase 1 103577-45-3 3883
3
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
4
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
5 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
6 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Antacids Phase 4,Phase 3,Phase 2,Phase 1
8 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
9
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
10
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
11
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
12
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 6006 143
13
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
14
Esomeprazole Approved, Investigational Phase 3,Phase 1 161796-78-7, 119141-88-7 4594 9579578
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
17 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
18 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
19 Vitamin B9 Phase 2, Phase 3
20 Immunologic Factors Phase 2, Phase 3,Phase 1
21 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
22 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
23 Folate Phase 2, Phase 3
24 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
25 Antimetabolites Phase 2, Phase 3,Phase 1
26 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
27 Calcium, Dietary Phase 3,Phase 2,Phase 1
28 Cinacalcet Hydrochloride Phase 3
29 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
30 Calcimimetic Agents Phase 3
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
32 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
33 Cola Phase 3,Phase 1
34 Central Nervous System Depressants Phase 3
35 Adjuvants, Anesthesia Phase 3
36 Anesthetics, Intravenous Phase 3
37 Analgesics, Opioid Phase 3
38 Peripheral Nervous System Agents Phase 3
39 Anesthetics, General Phase 3
40 Analgesics Phase 3
41 Narcotics Phase 3
42 Anesthetics Phase 3
43
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
44
Doxorubicin Approved, Investigational Phase 2,Not Applicable 23214-92-8 31703
45
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
46
Pancrelipase Approved, Investigational Phase 2,Phase 1 53608-75-6
47
Omeprazole Approved, Investigational, Vet_approved Phase 2,Phase 1 73590-58-6 4594
48
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
49
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
50
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
2 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
3 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
4 Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Completed NCT00079833 Phase 3 Esomeprazole magnesium (Nexium)
5 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
6 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
9 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
10 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
11 Effect of G17DT in Patients With Stage II/III Colorectal Cancer Completed NCT02518373 Phase 2 Omeprazole
12 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
13 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
14 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
15 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
16 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
17 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
18 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
19 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
20 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
21 EPO906 in Carcinoid and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B
22 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
23 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT01229943 Phase 2 Everolimus;Octreotide Acetate
24 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Active, not recruiting NCT02259725 Phase 2 regorafenib
25 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
26 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
27 YF476 and Type II Gastric Carcinoids Enrolling by invitation NCT02454075 Phase 2 YF476
28 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
29 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
30 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
31 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
32 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
33 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
34 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
35 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
36 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
37 A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants. Completed NCT00942175 Phase 1 Clopidogrel;Clopidogrel and Lansoprazole;Clopidogrel and Dexlansoprazole;Clopidogrel and Omeprazole;Clopidogrel and Esomeprazole
38 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
39 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
40 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
41 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
42 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
43 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
44 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
45 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
46 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376
47 Treatment of Zollinger-Ellison Syndrome Completed NCT00001241
48 Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome Completed NCT00001254
49 Nexium Capsules Clinical Experience Investigation Completed NCT01434485
50 Evaluating Patients With Abnormal Levels of Gastric Acid Completed NCT00001240

Search NIH Clinical Center for Zollinger-Ellison Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: zollinger-ellison syndrome

Sources

Genetic Tests for Zollinger-Ellison Syndrome

About this section

Genetic tests related to Zollinger-Ellison Syndrome:

# Genetic test Affiliating Genes
1 Zollinger-Ellison Syndrome 29
Sources

Anatomical Context for Zollinger-Ellison Syndrome

About this section

MalaCards organs/tissues related to Zollinger-Ellison Syndrome:

41
Pancreas, Testes, Pituitary, Small Intestine, Liver, Thyroid, Lymph Node
Sources

Publications for Zollinger-Ellison Syndrome

About this section

Articles related to Zollinger-Ellison Syndrome:

(show top 50) (show all 878)
# Title Authors Year
1
Gastric Neuroendocrine Tumor and Duodenal Gastrinoma With Chronic Autoimmune Atrophic Gastritis. ( 30531243 )
2019
2
Prospective Evaluation of Results of Reoperation in Zollinger-Ellison Syndrome. ( 29517561 )
2018
3
Gastrinoma and Zollinger-Ellison syndrome in canids: a literature review and a case in a Mexican gray wolf. ( 29860931 )
2018
4
Large primary hepatic gastrinoma in young patient treated with trisegmentectomy: A case report and review of the literature. ( 30079138 )
2018
5
Gastrinoma of Cystic Duct: A Rare Association With Multiple Endocrine Neoplasia Type 1. ( 30344820 )
2018
6
A rare cause of upper gastrointestinal bleeding: Primary gastrinoma of the lesser omentum. ( 30361100 )
2018
7
Management of Primary Lymph Nodal Gastrinoma With Liver Metastases Resulting in Zollinger-Ellison Syndrome. ( 30394927 )
2018
8
Diagnosis and management of Zollinger-Ellison syndrome in 2017. ( 28949124 )
2017
9
A Perplexing Case of Abdominal Pain That Led to the Diagnosis of Zollinger-Ellison Syndrome. ( 28321346 )
2017
10
Gastrointestinal: Zollinger-Ellison Syndrome: A rare cause of chronic diarrhea and abdominal pain. ( 28639271 )
2017
11
The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? ( 29019150 )
2017
12
Zollinger-Ellison Syndrome in a 12-year-old Child. ( 28694576 )
2017
13
Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. ( 29326808 )
2017
14
Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome. ( 28776139 )
2017
15
Zollinger-Ellison Syndrome: A Rare Case of Chronic Diarrhea. ( 28058079 )
2016
16
Zollinger-Ellison syndrome: an unusual case of chronic diarrhoea in a child. ( 28028304 )
2016
17
Zollinger-Ellison Syndrome Associated with von Recklinghausen Disease: Case Report and Literature Review. ( 27292293 )
2016
18
Assessing for multiple endocrine neoplasia type 1 in patients evaluated for Zollinger-Ellison Syndrome - clues to a safer diagnostic process. ( 28011308 )
2016
19
Medical management of gastrinoma in a cat. ( 28491421 )
2016
20
Sporadic, Primary Lymph Node Gastrinoma. ( 30454306 )
2016
21
Weight Gain in Zollinger-Ellison Syndrome After Acid Suppression. ( 26164604 )
2016
22
Zollinger-Ellison syndrome: Revelation of the gastrinoma triangle. ( 27408649 )
2015
23
Intraoperative near-infrared fluorescence visualization of theA duodenal gastrinoma in a patient withA Zollinger-Ellison syndrome. ( 26209566 )
2015
24
From hypomagnesaemia to Zollinger-Ellison syndrome: an adverse effect of a proton pump inhibitor. ( 25274557 )
2014
25
Severe symptomatic hypomagnesaemia induced by the chronic use of proton pump inhibitors: a case report of a patient with Zollinger-Ellison syndrome. ( 24635401 )
2014
26
Zollinger-ellison syndrome: classical considerations and current controversies. ( 24319020 )
2014
27
Metastatic gastrinoma in a pediatric patient with zollinger-ellison syndrome. ( 23426004 )
2014
28
Primary lymph node gastrinoma. A diagnosis of exclusion. A case for duodenotomy in the setting of a negative imaging for primary tumor: A case report and review of the literature. ( 25462049 )
2014
29
Secretin stimulation test for gastrin release in Zollinger-Ellison syndrome: to do or not to do? ( 23851427 )
2013
30
Missed opportunity in Zollinger-Ellison syndrome research. ( 23270867 )
2013
31
A case of Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1 with urolithiasis as the initial presentation. ( 23877214 )
2013
32
Zollinger-Ellison syndrome. ( 24641468 )
2013
33
Current management of the zollinger-ellison syndrome. ( 25293453 )
2013
34
Pharmacotherapy of Zollinger-Ellison syndrome. ( 23363383 )
2013
35
An unusual presentation of zollinger-ellison syndrome. ( 23466991 )
2013
36
Multiple gastrinomas of the duodenum in a patient with sporadic Zollinger-Ellison syndrome. ( 23613167 )
2013
37
Zollinger-Ellison syndrome: recent advances and controversies. ( 24100728 )
2013
38
Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. ( 23645327 )
2013
39
Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome. ( 23851430 )
2013
40
A case of Zollinger-Ellison syndrome diagnosed by duodenal ulcer perforation into the gallbladder. ( 23357498 )
2013
41
Current management of the Zollinger-Ellison syndrome. ( 24298844 )
2013
42
The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. ( 21871248 )
2012
43
Primary hepatic gastrinoma as an unusual manifestation of zollinger-ellison syndrome. ( 23271988 )
2012
44
Abdominal pain and liver lesions in Zollinger-Ellison syndrome. ( 21760542 )
2012
45
Diagnosis of Zollinger-Ellison syndrome: increasingly difficult. ( 23112541 )
2012
46
Importance of surveillance for multiple endocrine neoplasia-1 and surgery in patients with sporadic Zollinger-Ellison syndrome. ( 22902777 )
2012
47
Value of surgery in patients with negative imaging and sporadic Zollinger-Ellison syndrome. ( 22868363 )
2012
48
Primary hepatic gastrinoma causing zollinger-ellison syndrome: a rare and challenging diagnosis. ( 24213231 )
2012
49
A case of primary intrahepatic gastrinoma. ( 27326276 )
2012
50
Hemobilia due to biliary intraepithelial neoplasia associated with Zollinger-Ellison syndrome. ( 26182319 )
2012
Sources

Variations for Zollinger-Ellison Syndrome

About this section
Sources

Expression for Zollinger-Ellison Syndrome

About this section
Search GEO for disease gene expression data for Zollinger-Ellison Syndrome.
Sources

Pathways for Zollinger-Ellison Syndrome

About this section

Pathways related to Zollinger-Ellison Syndrome according to KEGG:

37
# Name Kegg Source Accession
1 Gastric acid secretion hsa04971

Pathways related to Zollinger-Ellison Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 66
Show member pathways
 13.56 GAST GHRH HRH2 MEN1 NTS SCT
2
Peptide ligand-binding receptors 66
Show member pathways
 13.03 GHRH HRH2 NTS SCT SST
3
Salivary secretion 37
Show member pathways
 11.65 GAST HRH2 SST
4
G alpha (s) signalling events 66
11.5 GHRH HRH2 SCT
5
Gastric acid production 1
9.8 GAST SCT
6
Secretion of Hydrochloric Acid in Parietal Cells 1
9.32 GAST HRH2
Sources

GO Terms for Zollinger-Ellison Syndrome

About this section

Cellular components related to Zollinger-Ellison Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.35 CHGA GAST GHRH SCT SST
2 axon terminus GO:0043679 9.16 GHRH NTS
3 extracellular region GO:0005576 9.1 CHGA GAST GHRH NTS SCT SST

Biological processes related to Zollinger-Ellison Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.43 GAST GHRH HRH2 NTS SCT SST
2 response to food GO:0032094 9.16 GAST GHRH
3 regulation of signaling receptor activity GO:0010469 9.02 GAST GHRH NTS SCT SST

Molecular functions related to Zollinger-Ellison Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 GHRH NTS
2 hormone activity GO:0005179 8.92 GAST GHRH SCT SST
Sources

Sources for Zollinger-Ellison Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....